Ronald P Pelletier
Overview
Explore the profile of Ronald P Pelletier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
408
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Long J, Motter J, Jackson K, Chen J, Orandi B, Montgomery R, et al.
Am J Transplant
. 2023 Sep;
23(12):1980-1989.
PMID: 37748554
Older compatible living donor kidney transplant (CLDKT) recipients have higher mortality and death-censored graft failure (DCGF) compared to younger recipients. These risks may be amplified in older incompatible living donor...
2.
Motter J, Jackson K, Long J, Waldram M, Orandi B, Montgomery R, et al.
Am J Transplant
. 2020 Dec;
21(4):1612-1621.
PMID: 33370502
Incompatible living donor kidney transplant recipients (ILDKTr) have pre-existing donor-specific antibody (DSA) that, despite desensitization, may persist or reappear with resulting consequences, including delayed graft function (DGF) and acute rejection...
3.
Jain D, Rajab A, Young J, Yin D, Nadasdy T, Chong A, et al.
Am J Transplant
. 2020 Apr;
20(10):2675-2685.
PMID: 32243663
Active antibody-mediated rejection (AMR) is a potentially devastating complication and consistently effective treatment remains elusive. We hypothesized that the reversal of acute AMR requires rapid elimination of antibody-secreting plasma cells...
4.
Jackson K, Long J, Motter J, Bowring M, Chen J, Waldram M, et al.
Transplantation
. 2020 Apr;
105(2):436-442.
PMID: 32235255
Background: Desensitization protocols for HLA-incompatible living donor kidney transplantation (ILDKT) vary across centers. The impact of these, as well as other practice variations, on ILDKT outcomes remains unknown. Methods: We...
5.
Nguyen M, Avila C, Brock G, Benedict J, James I, El-Hinnawi A, et al.
Clin Transplant
. 2020 Feb;
34(3):e13822.
PMID: 32037573
Background: Hospital readmission (HR) after surgery is considered a quality metric. Methods: Data on 2371 first-time adult kidney transplant (KT) recipients were collected to analyze the "early" (≤30 days) and...
6.
Zimmerer J, Basinger M, Ringwald B, Abdel-Rasoul M, Pelletier R, Rajab A, et al.
Transplantation
. 2020 Feb;
104(11):2424-2434.
PMID: 32032292
Background: We recently reported that a novel CXCR5IFN-γCD8 T-cell subset significantly inhibits posttransplant alloantibody production in a murine transplant model. These findings prompted the current study to investigate the association...
7.
Pelletier R, Balazs I, Adams P, Rajab A, DiPaola N, Henry M
Transpl Int
. 2017 Dec;
31(4):424-435.
PMID: 29265514
Development of donor-specific antibodies (DSA) after renal transplantation is known to be associated with worse graft survival, yet determining which specificities in which recipients are the most deleterious remains under...
8.
Orandi B, Luo X, King E, Garonzik-Wang J, Bae S, Montgomery R, et al.
Am J Transplant
. 2017 Aug;
18(3):650-658.
PMID: 28834181
Thirty percent of kidney transplant recipients are readmitted in the first month posttransplantation. Those with donor-specific antibody requiring desensitization and incompatible live donor kidney transplantation (ILDKT) constitute a unique subpopulation...
9.
Pelletier R, Pesavento T, Rajab A, Henry M
Clin Transplant
. 2016 May;
30(8):940-5.
PMID: 27218658
Background: Deceased donor (DD) kidney quality is determined by calculating the Kidney Donor Profile Index (KDPI). Optimizing high KDPI (≥85%) DD transplant outcome is challenging. This retrospective study was performed...
10.
Orandi B, Luo X, Massie A, Garonzik-Wang J, Lonze B, Ahmed R, et al.
N Engl J Med
. 2016 Mar;
374(10):940-50.
PMID: 26962729
Background: A report from a high-volume single center indicated a survival benefit of receiving a kidney transplant from an HLA-incompatible live donor as compared with remaining on the waiting list,...